Teva draws blank in phase 3 Tourette Syndrome trial

Teva’s late stage trials of a potential drug for Tourette Syndrome have drawn a blank, just when the troubled pharma needs to freshen up its portfolio.

Warren Buffet shocks Wall Street with Biogen gamble

Biogen is trying to resurrect two failed trials of its Alzheimer’s drug aducanumab – and superstar investor Warren Buffet thinks the volatile stock is worth gambling on as the company prepa

After rejection, NICE agrees to look again at migraine drug ...

Novartis' Mayzent EU approval offers SPMS patients new optio...

Novartis’ Mayzent has been approved in Europe for adults with secondary progressive multiple sclerosis (SPMS) and active disease.

Chasing Astellas, UK's KaNDy heads to phase 3 with menopause...

UK biotech KaNDy Therapeutics is heading to phase 3 with its non-hormonal menopause drug, after a mid-stage trial showed it reduced hot flashes as well as improved quality of life, setting

Neurocrine signs $400M-plus deal with Idorsia for epilepsy d...